Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Clinical Trial

An Efficacy and Safety Study of Remogliflozin in Obese Indian Type 2 Diabetes Mellitus Patients Who Were Inadequately Controlled on Insulin Glargine Plus other Oral Hypoglycemic Agents

Author(s): Anand Shankar*

Volume 17, Issue 7, 2021

Published on: 22 December, 2020

Article ID: e122120189341 Pages: 8

DOI: 10.2174/1573399817666201222102520

Price: $65

Abstract

Aims & Objectives: The objective of this retrospective study was to investigate the efficacy of adding remogliflozin to current insulin glargine plus two oral drug i.e. metformin and teneligliptin therapy in poorly controlled Indian type 2 diabetes.

Materials and Methods: 173 study participants were initially selected from patient database who continued on their insulin glargine or received an increased dose of insulin glargine along with other OHA based therapy (Group A) and 187 were selected who had received remogliflozin (100 mg BD) (Group B) in addition to insulin glargine along with other OHA based therapy. Glycated haemoglobin (HbA1c), total daily insulin dose, body weight, and the number of hypoglycemic events were recorded at weeks 0, 12 and 24.

Results: During the study, mean values of HbA1c, FBG and P2BG were significantly reduced in both groups. Insulin requirements decreased from 45.8 ± 16.7 IU/day to 38.5 ± 13.5 IU/day at week 12 (P < 0.001) and at week 24 even further decreased to 29.5 ± 14.5 IU/Day. Twenty three patients in group B were able to cease insulin treatment altogether after 24 week treatment. It has been observed that to attain tight blood glucose control, we need to increase insulin dose in group A from 45.5 ± 16.5 IU/Day to 51.5 ± 14.5 at week 12 (P<0.01), which further increased to 53.8 ± 12.8 IU/Day at week 24 (P<0.01). Adding remogliflozin showed significant effect on blood pressure (P < 0.001) and weight reduction (P < 0.001). It has been observed that 38% patients achieved targeted HbA1c (≤7%) in group B where it was 22% in group A.

Conclusion: Results demonstrate that in uncontrolled T2DM patients, remogliflozin 100 mg BD can successfully lay a foundation for prolonged good glycemic control. Early addition of remogliflozin with insulin glargine plus OHAs may be an alternative compared to intensive up titration of insulin daily dose in people with uncontrolled T2DM.

Keywords: Remogliflozin, insulin, T2DM, glycemic control, metformin, teneligliptin therapy, insulin dose.

[1]
Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: A randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28(2): 103-17.
[http://dx.doi.org/10.1016/0168-8227(95)01064-K] [PMID: 7587918]
[2]
Turner RC, Cull CA, Frighi V, Holman RR. UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281(21): 2005-12.
[http://dx.doi.org/10.1001/jama.281.21.2005] [PMID: 10359389]
[3]
Hammer H, Klinge A. Patients with type 2 diabetes inadequately controlled on premixed insulin: Effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice. Int J Clin Pract 2007; 61(12): 2009-18.
[http://dx.doi.org/10.1111/j.1742-1241.2007.01598.x] [PMID: 17997807]
[4]
Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): An open randomised controlled trial. Lancet 2008; 371(9618): 1073-84.
[http://dx.doi.org/10.1016/S0140-6736(08)60485-7] [PMID: 18374840]
[5]
Blicklé J-F, Hancu N, Piletic M, et al. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study. Diabetes Obes Metab 2009; 11(4): 379-86.
[http://dx.doi.org/10.1111/j.1463-1326.2008.00980.x] [PMID: 19087105]
[6]
Tamez-Pérez HE, Gonzalez-Guajardo EE, Tamez-Peña AL. Consensus statement by The American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2019 executive summary. Endocr Pract 2019; 25(6): 622.
[http://dx.doi.org/10.4158/1934-2403-25.6.622] [PMID: 31242125]
[7]
Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018; 61(12): 2461-98.
[http://dx.doi.org/10.1007/s00125-018-4729-5] [PMID: 30288571]
[8]
Wiviott SD, Raz I, Bonaca MP, et al. DECLARE–TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019; 380(4): 347-57.
[http://dx.doi.org/10.1056/NEJMoa1812389] [PMID: 30415602]
[9]
Zinman B, Wanner C, Lachin JM, et al. EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373(22): 2117-28.
[http://dx.doi.org/10.1056/NEJMoa1504720] [PMID: 26378978]
[10]
Wanner Ch, Inzucchi SE, Zinman B. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016; 375(18): 1801-2.
[http://dx.doi.org/10.1056/NEJMoa1515920] [PMID: 27806236]
[11]
Markham A. RemogliflozinEtabonate: First global approval. Drugs 2019; 79(10): 1157-61.
[http://dx.doi.org/10.1007/s40265-019-01150-9] [PMID: 31201711]
[12]
Dharmalingam M, Aravind SR, Thacker H, et al. Efficacy and safety of RemogliflozinEtabonate, a new sodium glucose co-transporter-2 inhibitor, in patients with type 2 diabetes mellitus: A 24-week, randomized, double-blind, active-controlled trial. Drugs 2020; 80(6): 587-600.
[http://dx.doi.org/10.1007/s40265-020-01285-0] [PMID: 32162274]
[13]
Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ 2006; 32(1)(Suppl.): 9S-18S.
[http://dx.doi.org/10.1177/0145721705285638] [PMID: 16439485]
[14]
Korytkowski M. When oral agents fail: Practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002; 26(Suppl. 3): S18-24.
[http://dx.doi.org/10.1038/sj.ijo.0802173] [PMID: 12174319]
[15]
Harris SB, Kapor J, Lank CN, Willan AR, Houston T. Clinical inertia in patients with T2DM requiring insulin in family practice. Can Fam Physician 2010; 56(12): e418-24.
[PMID: 21156883]
[16]
Rubin DJ, Rybin D, Doros G, McDonnell ME. Weight-based, insulin dose-related hypoglycemia in hospitalized patients with diabetes. Diabetes Care 2011; 34(8): 1723-8.
[http://dx.doi.org/10.2337/dc10-2434] [PMID: 21700919]
[17]
Shaefer CF, Reid TS, Dailey G, et al. Weight change in patients with type 2 diabetes starting basal insulin therapy: Correlates and impact on outcomes. Postgrad Med 2014; 126(6): 93-105.
[http://dx.doi.org/10.3810/pgm.2014.10.2824] [PMID: 25414938]
[18]
Larger E. Weight gain and insulin treatment. Diabetes Metab 2005; 31(4 part 2): 4S51-6.
[http://dx.doi.org/10.1016/S1262-3636(05)88268-0]
[19]
Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: Pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care 2005; 28(12): 2948-61.
[http://dx.doi.org/10.2337/diacare.28.12.2948] [PMID: 16306561]
[20]
Raskin P, Allen E, Hollander P, et al. INITIATE Study Group. Initiating insulin therapy in type 2 Diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care 2005; 28(2): 260-5.
[http://dx.doi.org/10.2337/diacare.28.2.260] [PMID: 15677776]
[21]
Douek IF, Allen SE, Ewings P, Gale EA, Bingley PJ. Metformin Trial Group. Continuing metformin when starting insulin in patients with Type 2 diabetes: A double-blind randomized placebo- controlled trial. Diabet Med 2005; 22(5): 634-40.
[http://dx.doi.org/10.1111/j.1464-5491.2005.01475.x] [PMID: 15842521]
[22]
Wilding JP, Woo V, Soler NG, et al. Dapagliflozin 006 Study Group. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial. Ann Intern Med 2012; 156(6): 405-15.
[http://dx.doi.org/10.7326/0003-4819-156-6-201203200-00003] [PMID: 22431673]
[23]
Rosenstock J, Jelaska A, Zeller C, Kim G, Broedl UC, Woerle HJ. EMPA-REG BASALTM trial investigators. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: A 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 2015; 17(10): 936-48.
[http://dx.doi.org/10.1111/dom.12503] [PMID: 26040302]
[24]
Fonseca V, Gill J, Zhou R, Leahy J. An analysis of early insulin glargine added to metformin with or without sulfonylurea: Impact on glycaemic control and hypoglycaemia. Diabetes Obes Metab 2011; 13(9): 814-22.
[http://dx.doi.org/10.1111/j.1463-1326.2011.01412.x] [PMID: 21481127]
[25]
Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia 2007; 50(6): 1148-55.
[http://dx.doi.org/10.1007/s00125-007-0633-0] [PMID: 17387446]
[26]
Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S. Pioglitazone 014 Study Group. Efficacy and safety of pioglitazone in type 2 diabetes: A randomised, placebo-controlled study in patients receiving stable insulin therapy. Int J Clin Pract 2002; 56(4): 251-7.
[PMID: 12074206]
[27]
Yki-Järvinen H, Rosenstock J, Durán-Garcia S, et al. Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: A ≥52-week randomized, double-blind study. Diabetes Care 2013; 36(12): 3875-81.
[http://dx.doi.org/10.2337/dc12-2718] [PMID: 24062327]
[28]
Pontiroli AE, Miele L, Morabito A. Metabolic control and risk of hypoglycaemia during the first year of intensive insulin treatment in type 2 diabetes: Systematic review and meta-analysis. Diabetes Obes Metab 2012; 14(5): 433-46.
[http://dx.doi.org/10.1111/j.1463-1326.2011.01543.x] [PMID: 22142056]
[29]
Sykes AP, Kemp GL, Dobbins R, et al. Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes. Diabetes Obes Metab 2015; 17(1): 98-101.
[http://dx.doi.org/10.1111/dom.12393] [PMID: 25238025]
[30]
Mohan V, Mithal A, Joshi SR, Aravind SR, Chowdhury S. Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy. Drug Des Devel Ther 2020; 14: 2487-501.
[http://dx.doi.org/10.2147/DDDT.S221093] [PMID: 32612352]

Rights & Permissions Print Cite
Article Metrics
17
1
© 2024 Bentham Science Publishers | Privacy Policy